A phase 2 double-blind randomized study of oral enzastaurin HCl versus placebo concurrently with pemetrexed (Alimta) as second-line therapy in patients with advanced or metastatic non-small cell lung cancer

Trial Profile

A phase 2 double-blind randomized study of oral enzastaurin HCl versus placebo concurrently with pemetrexed (Alimta) as second-line therapy in patients with advanced or metastatic non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Enzastaurin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2010 Results presented in the Journal of Thoracic Oncology.
    • 04 Aug 2009 Results presented at IASLC 2009.
    • 01 Aug 2009 Tolerability and quality of life results have been reported at the 13th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top